AbbVie, Galapagos aim to beat Vertex in CF

AbbVie has signed a $405m deal with Galapagos of Belgium which will see the two companies pool resources with the aim of developing a superior treatment for cystic fibrosis to Vertex Pharmaceuticals' Kalydeco (ivacaftor). More than a hundred staff from the two partners will work together to advance Galapagos's early-stage in-house research and develop CF transmembrane conductance regulator (CFTR) therapies.